Sage Therapeutics, Inc. – NASDAQ:SAGE

Sage Therapeutics stock price today

$8.69
+3.14
+56.86%
Financial Health
0
1
2
3
4
5
6
7
8
9

Sage Therapeutics stock price monthly change

-52.89%
month

Sage Therapeutics stock price quarterly change

-52.89%
quarter

Sage Therapeutics stock price yearly change

-75.11%
year

Sage Therapeutics key metrics

Market Cap
334.00M
Enterprise value
2.42B
P/E
-4.91
EV/Sales
315.39
EV/EBITDA
-4.68
Price/Sales
334.98
Price/Book
2.05
PEG ratio
0.32
EPS
-8.4
Revenue
91.06M
EBITDA
-473.61M
Income
-503.14M
Revenue Q/Q
139.89%
Revenue Y/Y
868.86%
Profit margin
-6930.97%
Oper. margin
-7115.75%
Gross margin
89.42%
EBIT margin
-7115.75%
EBITDA margin
-520.09%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Sage Therapeutics stock price history

Sage Therapeutics stock forecast

Sage Therapeutics financial statements

Average Price Target
Last Year

$12.86

Potential upside: 47.95%

Based on estimate of 7 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Sage Therapeutics, Inc. (NASDAQ:SAGE): Profit margin
Jun 2023 2.47M -160.32M -6480.4%
Sep 2023 2.71M -201.63M -7423.78%
Dec 2023 77.97M -32.70M -41.95%
Mar 2024 7.90M -108.48M -1372.85%
Sage Therapeutics, Inc. (NASDAQ:SAGE): Debt to assets
Jun 2023 1082288000 97.91M 9.05%
Sep 2023 949663000 133.00M 14.01%
Dec 2023 882277000 82.74M 9.38%
Mar 2024 767600000 61.79M 8.05%
Sage Therapeutics, Inc. (NASDAQ:SAGE): Cash Flow
Jun 2023 -131.51M 45.59M 847K
Sep 2023 -135.86M 160.39M 2.77M
Dec 2023 -119.51M 42.06M -262K
Mar 2024 -37.83M 139.43M 1.55M

Sage Therapeutics alternative data

Sage Therapeutics, Inc. (NASDAQ:SAGE): Employee count
Aug 2023 689
Sep 2023 689
Oct 2023 689
Nov 2023 689
Dec 2023 689
Jan 2024 689
Feb 2024 689
Mar 2024 487
Apr 2024 487
May 2024 487
Jun 2024 487
Jul 2024 487

Sage Therapeutics other data

84.24% -0.50%
of SAGE is owned by hedge funds
49.42M -422.30K
shares is hold by hedge funds

Sage Therapeutics, Inc. (NASDAQ:SAGE): Insider trades (number of shares)
Period Buy Sel
Nov 2022 14500 0
Feb 2023 0 11643
May 2023 1000 0
Aug 2023 2000 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
IGUCHI KIMI officer: CFO & Tr.. Common Stock 1,642 $1.36 $2,233
Option
IGUCHI KIMI officer: CFO & Tr.. Stock Option (Right to Buy) 1,642 $1.36 $2,233
Purchase
BARRETT ELIZABETH director Common Stock 2,000 $18.64 $37,278
Purchase
BARRETT ELIZABETH director Common Stock 1,000 $50.5 $50,500
Option
IGUCHI KIMI officer: CFO & Tr.. Stock Option (Right to Buy) 3,000 $1.36 $4,080
Option
IGUCHI KIMI officer: CFO & Tr.. Common Stock 3,000 $1.36 $4,080
Option
IGUCHI KIMI officer: CFO & Tr.. Stock Option (Right to Buy) 250 $1.36 $340
Option
IGUCHI KIMI officer: CFO & Tr.. Common Stock 250 $1.36 $340
Option
IGUCHI KIMI officer: CFO & Tr.. Stock Option (Right to Buy) 750 $1.36 $1,020
Option
IGUCHI KIMI officer: CFO & Tr.. Common Stock 750 $1.36 $1,020
Patent
Grant
Filling date: 26 Apr 2019 Issue date: 30 Aug 2022
Grant
Filling date: 15 Jul 2020 Issue date: 9 Aug 2022
Grant
Filling date: 11 Jul 2017 Issue date: 26 Jul 2022
Application
Filling date: 15 Mar 2022 Issue date: 14 Jul 2022
Application
Filling date: 15 Mar 2022 Issue date: 7 Jul 2022
Application
Filling date: 6 Aug 2021 Issue date: 2 Jun 2022
Grant
Filling date: 10 Jul 2019 Issue date: 31 May 2022
Application
Filling date: 3 Feb 2022 Issue date: 19 May 2022
Application
Filling date: 23 Dec 2021 Issue date: 14 Apr 2022
Application
Filling date: 14 Sep 2018 Issue date: 14 Apr 2022
Monday, 23 December 2024
zacks.com
Tuesday, 26 November 2024
businesswire.com
Thursday, 21 November 2024
zacks.com
Wednesday, 20 November 2024
benzinga.com
marketwatch.com
reuters.com
businesswire.com
Wednesday, 30 October 2024
zacks.com
Tuesday, 29 October 2024
seekingalpha.com
zacks.com
Monday, 28 October 2024
accesswire.com
globenewswire.com
accesswire.com
prnewswire.com
prnewswire.com
accesswire.com
accesswire.com
prnewswire.com
Sunday, 27 October 2024
accesswire.com
accesswire.com
accesswire.com
Saturday, 26 October 2024
prnewswire.com
accesswire.com
Friday, 25 October 2024
globenewswire.com
prnewswire.com
businesswire.com
accesswire.com
prnewswire.com
Thursday, 24 October 2024
prnewswire.com
Wednesday, 23 October 2024
globenewswire.com
  • What's the price of Sage Therapeutics stock today?

    One share of Sage Therapeutics stock can currently be purchased for approximately $8.69.

  • When is Sage Therapeutics's next earnings date?

    Unfortunately, Sage Therapeutics's (SAGE) next earnings date is currently unknown.

  • Does Sage Therapeutics pay dividends?

    No, Sage Therapeutics does not pay dividends.

  • How much money does Sage Therapeutics make?

    Sage Therapeutics has a market capitalization of 334.00M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1024.84% to 86.46M US dollars.

  • What is Sage Therapeutics's stock symbol?

    Sage Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SAGE".

  • What is Sage Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Sage Therapeutics?

    Shares of Sage Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Sage Therapeutics's key executives?

    Sage Therapeutics's management team includes the following people:

    • Dr. Jeffrey M. Jonas Chief Innovation Officer, Chair of the Science & Technology Forum and Director(age: 72, pay: $1,200,000)
    • Ms. Anne Marie Cook Senior Vice President, Gen. Counsel & Sec.(age: 63, pay: $668,150)
    • Dr. Albert J. Robichaud Ph.D. Chief Scientific Officer(age: 64, pay: $657,130)
    • Ms. Kimi E. Iguchi Chief Financial Officer & Treasurer(age: 63, pay: $645,260)
    • Mr. Barry E. Greene Pres, Chief Executive Officer & Director(age: 62, pay: $54,190)
  • How many employees does Sage Therapeutics have?

    As Jul 2024, Sage Therapeutics employs 487 workers.

  • When Sage Therapeutics went public?

    Sage Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 18 Jul 2014.

  • What is Sage Therapeutics's official website?

    The official website for Sage Therapeutics is sagerx.com.

  • Where are Sage Therapeutics's headquarters?

    Sage Therapeutics is headquartered at 215 First Street, Cambridge, MA.

  • How can i contact Sage Therapeutics?

    Sage Therapeutics's mailing address is 215 First Street, Cambridge, MA and company can be reached via phone at +61 72998380.

  • What is Sage Therapeutics stock forecast & price target?

    Based on 7 Wall Street analysts` predicted price targets for Sage Therapeutics in the last 12 months, the avarage price target is $12.86. The average price target represents a 47.95% change from the last price of $8.69.

Sage Therapeutics company profile:

Sage Therapeutics, Inc.

sagerx.com
Exchange:

NASDAQ

Full time employees:

487

Industry:

Biotechnology

Sector:

Healthcare

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

215 First Street
Cambridge, MA 02142

CIK: 0001597553
ISIN: US78667J1088
CUSIP: 78667J108